

49. **Zauber AG, Winawer SJ, O'Brien MJ, et al.** Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med* 2012; 366(8):687–696. doi:10.1056/NEJMoa1100370
50. **Nishihara R, Wu K, Lochhead P, et al.** Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013; 369(12):1095–1105. doi:10.1056/NEJMoa1301969
51. **Løberg M, Kalager M, Holme Ø, Hoff G, Adami HO, Bretthauer M.** Long-term colorectal-cancer mortality after adenoma removal. *N Engl J Med* 2014; 371(9):799–807. doi:10.1056/NEJMoa1315870
52. **Manser CN, Bachmann LM, Brunner J, Hunold F, Bauerfeind P, Maret UA.** Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. *Gastrointest Endosc* 2012; 76(1):110–117. doi:10.1016/j.gie.2012.02.040
53. **Winawer SJ, Zauber AG, Ho MN, et al.** Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med* 1993; 329(27):1977–1981. doi:10.1056/NEJM199312303292701
54. **Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M; Italian Multicentre Study Group.** Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. *Gut* 2001; 48(6):812–815. PMID:11358901
55. **Muller AD, Sonnenberg A.** Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. *Ann Intern Med* 1995; 123(12):904–910. PMID:7486484
56. **Knudsen AB, Zauber AG, Rutter CM, et al.** Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. *JAMA* 2016; 315(23):2595–2609. doi:10.1001/jama.2016.6828
57. **Rex DK, Schoenfeld PS, Cohen J, et al.** Quality indicators for colonoscopy. *Gastrointest Endosc* 2015; 81(1):31–53. doi:10.1016/j.gie.2014.07.058
58. **Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL.** Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. *N Engl J Med* 2006; 355(24):2533–2541. doi:10.1056/NEJMoa055498
59. **Corley DA, Levin TR, Doubeni CA.** Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014; 370(26):2541. doi:10.1056/NEJMc1405329
60. **Lin JS, Piper MA, Perdue LA, et al.** Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2016; 315(23):2576–2594. doi:10.1001/jama.2016.3332
61. **Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI.** Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. *J Natl Cancer Inst* 2003; 95(3):230–236. PMID:12569145
62. **Warren JL, Klabunde CN, Mariotto AB, et al.** Adverse events after outpatient colonoscopy in the Medicare population. *Ann Intern Med* 2009; 150(12):849–857, W152. PMID:19528563
63. **Quintero E, Carrillo M, Gimeno-García AZ, et al.** Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening. *Gastroenterology* 2014; 147(5):1021–130.e1. doi:10.1053/j.gastro.2014.08.004
64. **Leddin D, Lieberman DA, Tse F, et al.** Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma: the Canadian Association of Gastroenterology Banff Consensus. *Gastroenterology* 2018; 155(5):1325–1347.e3. doi:10.1053/j.gastro.2018.08.017
65. **Quintero E, Castells A, Bujanda L, et al; COLONPREV Study Investigators.** Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. *N Engl J Med* 2012; 366(8):697–706. doi:10.1056/NEJMoa1108895
66. **Gupta S, Halm EA, Rockey DC, et al.** Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. *JAMA Intern Med* 2013; 173(18):1725–1732. doi:10.1001/jamainternmed.2013.9294
67. **Segnan N, Senore C, Andreoni B, et al; SCORE3 Working Group-Italy.** Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. *Gastroenterology* 2007; 132(7):2304–2312. doi:10.1053/j.gastro.2007.03.030

ADDRESS: Gautam Mankaney, MD, Digestive Disease & Surgery Institute, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mankaney@ccf.org

CORRECTION

Subclinical hypothyroidism

FEBRUARY 2019

In Azim S, Nasr C, “Subclinical hypothyroidism: When to treat,” *Cleve Clin J Med* 2019; 86(2):101–110, on page 103, in the section “Subclinical hypothyroidism can resolve or progress,” the sentence “The

rate of progression to overt hypothyroidism is estimated to be 33% to 35% over 10 to 20 years of follow-up” contained an error. The correct rate of progression is 33% to 55%. This error has been corrected online.